Consultant, PhD
Ulla Lei Larsen
Department of Anaesthesiology & Intensive Care, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark
| Project management | ||
| Project status | Open | |
| Data collection dates | ||
| Start | 01.05.2025 | |
| End | 31.12.2026 | |
Hypertem Intraperitoneal Kemoterapi (HIPEC) til ovariecancer og patienternes efterfølgende forløb på et intensivt afsnit
Short summary
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a newer adjuvant therapy used in extension of cytoreductive surgery for ovarian cancer. The aim of our study is to describe the patient population who underwent a HIPEC-procedure during elective surgery for ovarian cancer and their need for intensive care. Secondly, to compare HIPEC-patients vs non-HIPEC patients on various outcome variables such as need for postoperative intensive care treatment and length of ICU-stay
Rationale
Hyperthermic intraperitoneal chemotherapy (HIPEC) is an adjuvant therapy recently introduced at Odense University Hospital. HIPEC is performed in extension of cytoreductive surgery for ovarian cancer and has shown increased survival in the more advanced stages. The procedure involves application of heated intraabdominal chemotherapy for hours during the perioperative period and increases the overall duration of surgery. Current practise at Odense University Hospital includes admission to the intensive care unit in the immediate postoperative period, for further treatment and observation. We speculate an increased need for intensive care treatment and longer ICU-stay for patients undergoing HIPEC procedure due to an added risk of adverse effects.
Description of the cohort
All patients with ovarian cancer at Odense University Hospital, who were scheduled for postoperative admission to ICU, was eligible for inclusion in the study
Data and biological material
Data from the Electronic patients journal (EPJ) and the Critical informations system (CIS) from ICU.